We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · January 30, 2023

Effect of Dapagliflozin in Patients With Heart Failure With Improved Ejection Fraction

Nature Medicine


Additional Info

Nature Medicine
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
Nat. Med. 2022 Dec 01;28(12)2504-2511, O Vardeny, JC Fang, AS Desai, PS Jhund, B Claggett, M Vaduganathan, RA de Boer, AF Hernandez, CSP Lam, SE Inzucchi, FA Martinez, MN Kosiborod, D DeMets, E O'Meara, S Zieroth, J Comin-Colet, J Drozdz, CE Chiang, M Kitakaze, M Petersson, D Lindholm, AM Langkilde, JJV McMurray, SD Solomon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading